Dose and Administration definition

Dose and Administration. Atomoxetine is normally given as a single dose in the morning. Patients who do not achieve a satisfactory clinical response (tolerability [e.g., nausea or somnolence] or efficacy) when taking atomoxetine as a single daily dose might benefit from taking it as twice daily evenly divided doses in the morning and late afternoon or early evening. In some cases it might be appropriate to continue treatment into adulthood. Consideration should be given to dose reduction or interrupting therapy in patients who are not growing or gaining weight satisfactorily. In cases of significant adverse effects, atomoxetine may be stopped abruptly; otherwise the drug may be tapered off over a suitable time period. Dosing up to 70 kg Body Weight: Initiate at a total daily dose of approximately 0.5mg/kg. This dose should be maintained for a minimum of 7 days before upward dose titration according to clinical response and tolerability. The recommended maintenance dose is approximately 1.2mg/kg/day (depending on the patient's weight and available dosage strengths of atomoxetine). No additional benefit has been demonstrated for doses higher than 1.2mg/kg/day. Dosing over 70 kg Body Weight: Initiate at a total daily dose of 40 mg. This dose should be maintained for a minimum of 7 days before upward dose titration according to clinical response and tolerability. The recommended maintenance dose is 80 mg. No additional benefit has been demonstrated for doses higher than 80 mg. The maximum recommended total daily dose is 100 mg. Renal insufficiency: Atomoxetine can be administered to ADHD patients with end-stage renal disease or lesser degrees of renal insufficiency using the usual dosing regimen. Atomoxetine may exacerbate hypertension in patients with end-stage renal disease. Hepatic insufficiency: For patients with moderate hepatic insufficiency (Child-Xxxx Class B), initial and target doses should be reduced to 50% of the usual dose. For patients with severe hepatic insufficiency (Child-Xxxx Class C), initial dose and target doses should be reduced to 25% of usual dose. Metabolic Insufficiency: Patients with the genotype corresponding to a non functional CYP2D6 enzyme (CYP2D6 poor metabolisers) have a several-fold higher exposure to atomoxetine when compared to patients with a functional enzyme and are therefore at higher risk of adverse events. A lower starting dose and slower up titration of the dose may be considered.
Dose and Administration. Available as 200 mg tablets in 60 tablet packs. Adults (including the elderly: The minimum effective dose should be employed. This dose should not exceed 6.5 mg/kg/day (calculated from ideal body weight and not actual body weight) and will be either 200 mg or 400 mg per day. In patients able to receive 400 mg daily initial doses to be divided. The dose can be reduced to 200 mg when further improvement is evident. The maintenance dose should be increased to 400 mg daily if the response lessens. Each dose should be taken with a meal or glass of milk. Hydroxychloroquine is cumulative in action and will require several weeks to exert its beneficial effects, whereas minor side effects may occur relatively early. For rheumatic disease treatment should be discontinued if there is no improvement by 6 months. In light-sensitive diseases, treatment should only be given during periods of maximum exposure to light.
Dose and Administration. Apomorphine is administered by the subcutaneous (SC) route. It can be delivered either as continuous SC infusion via a pump (APO-go® pre-filled syringe 50 mg/10 ml solution for infusion; Dacepton® vials 100 mg/20 ml solution for infusion) or as an intermittent SC pen injection (APO-go® PEN 30 mg/3ml solution for injection; Dacepton® cartridge 30 mg/3 ml solution for injection). For full details of initiating treatment: refer to the Summary of product Characteristics (SPC). The optimum dose of apomorphine needs to be determined on an individual patient basis. During treatment with a pen- injector, the daily dose varies widely between patients and is typically within the range of 3 – 30 mg, with each dose administered at the start of an ‘off’ episode. Individual bolus injections and the total daily dose should not exceed 10 mg and 100 mg respectively. For patients whose overall control remains unsatisfactory using intermittent injections, or who require many and frequent injections (> 6 per day), apomorphine can be administered as a continuous SC infusion via pump. Maximum daily apomorphine dose should not exceed 100 mg. Patients selected for a pen-injector should be able to recognise the onset of their ‘off’ symptoms and be capable of injecting themselves, or have a responsible carer able to inject for them when required. Monitoring: Hospital team/PDNS • Monitoring /evaluation of adverse drug reactions • Monitoring /evaluation of symptomatic response • Communication of results / treatment changes to primary care team • Check full blood count, Xxxxxx test and LFT 4-6 months Primary care team • Monitor general health / well being • Prescribe ongoing drug therapy as recommended by hospital team • Inform hospital team if side effects or complications • Inform hospital is shared care is declined Contra- indications: • Neuropsychiatric problems / dementia • Hepatic impairment • Respiratory or CNS depression • Not for use in under 18 years Cautions: • Pregnancy / breast feeding • Pulmonary / cardiovascular disease/ endocrine disease • Renal disease • Postural hypotension • Prolonged QT interval avoid if high risk of torsades de pointes arrhythmia • Elderly Haemolytic anaemia in patients with apomorphine and levodopa reported. Xxxxxx test and LFT needed at 4 -6 monthly intervals

Examples of Dose and Administration in a sentence

  • Dose and Administration Oral dosing: 550 mg twice daily with a glass of water.

  • Fluoxetine Dose and Administration Method Differentially Affect Hippocampal Plasticity in Adult Female Rats.

  • Dose and Administration: Prophylaxis: One tablet (250 mg/100 mg) taken orally, daily.

  • Dose and Administration All eligible subjects were randomized 1:1:1:1 to placebo, paliperidone ER Low, Medium or High dose group.

  • In these patients, consider reducing or stopping the opioid treatment if appropriate, using best practices for tapering of opioids (see section 4.2 Dose and Administration, Discontinuation of therapy).

  • Documents will then be transferred to the trial master file (TMF).9.3 Dose and Administration FCM will be administered based on the following: Baseline Hb (g/dL) 9.4 Stopping Rules There are no formal stopping rules for the study but should the patient develop anaphylaxis or para-venous leak is observed, the infusion will be interrupted and patient treatment will be left to the attending physician.

  • This has implications for International Relations since the UN is the organisation where all the countries of the world meet to discuss how to achieve sustainable peace.

  • Dose and Administration The maximum licensed dose is 12 mg/day; however perampanel at doses of 4mg/day to 12mg/day has shown to be effective therapy in partial-onset seizures.

  • The University’s resources and assets, including, but not limited to, physical assets, software, communication systems, paid working time, and information must not be used for inappropriate or illegal purposes.

  • Dose and Administration: Dyspepsia, gastro-oesophageal reflux: Oral: Adult: 5–10 ml suspension 4 times daily between meals and at bedtime Child: 6–12 years 5 ml up to three times dailyHyperphosphataemia, Oral: Adult: 2–10 g daily in divided doses with meals Patient Advice.


More Definitions of Dose and Administration

Dose and Administration. Starting dose of Tostran® is 3g gel (Six metered doses, 60 mg of testosterone) applied once daily at approximately the same time each morning. Dose titration should be based on both serum testosterone levels and the existence of clinical signs and symptoms related to androgen deficiency. It should be taken into account that physiological testosterone levels decline with increasing age. The daily dose should not exceed 4 g of gel (80 mg testosterone). The dose can be applied to the abdomen (entire dose over an area of at least 10 by 30 cm), or to both inner thighs (one half of the dose over an area of at least 10 by 15 cm for each inner thigh). Daily rotation between the abdomen and inner thighs is recommended to minimise application site reactions Each full depression of the canister piston delivers one half gram of gel (10 mg testosterone).
Dose and Administration. Available as tablets containing 500 mg, 750 mg or 1,000 mg, as sachets containing 750 mg or 1000 mg. Patients who respond to Lanthanum therapy usually achieve acceptable serum phosphate levels at doses of 1,500 to 3,000 mg per day. Control of serum phosphate level has been demonstrated at doses starting from 750 mg per day. The maximum dose studied in clinical trials, in a limited number of patients, is 3,750 mg. Lanthanum should be taken with or immediately after food, with the daily dose divided between meals. Tablets must be chewed and not swallowed whole. Lanthanum oral powder can be used in patients who have difficulty chewing the tablets. Lanthanum oral powder is intended to be mixed with a small quantity of soft food (e.g. applesauce or other similar food product) and consumed immediately (within 15 minutes). The sachet must not be opened until ready to use. Once mixed with food, Lanthanum oral powder must not be stored for future use. Lanthanum oral powder is insoluble and must not be dissolved in liquid for administration. Serum phosphate levels should be monitored and the dose of Lanthanum titrated every two to three weeks until an acceptable serum phosphate level is reached, with regular monitoring thereafter. The use of Lanthanum in clinical studies beyond 2 years is currently limited. However, treatment of subjects with Lanthanum for up to 6 years has not demonstrated a change in the benefit/risk profile. The safety and efficacy of Lanthanum in children and adolescents below the age of 18 years has not been established. The effect of hepatic impairment on Lanthanum pharmacokinetics has not been assessed. Due to its mechanism of action and the lack of liver metabolism doses in hepatic impairment should not be modified, but patients should be monitored carefully.
Dose and Administration. A long-acting testosterone ester (testosterone enantate) or mixture of esters (Sustanon 250®) at 50 – 75 mg/month is used initially and escalated gradually every 6 months to 100 – 150 mg/month before changing to 250 mg 3 weekly after 3–4 years. Note: Potential pitfall: Sustanon 250® contains arachis oil, and therefore should be used with caution in those with peanut allergy (and soya allergy, due to crossreactivity)5 . The arachis oil does not contain peanut protein and therefore most individuals with peanut allergy will tolerate the preparation, unless their sensitivity is very high. Testosterone undecanoate (Restandol® ) starting at 40 mg once daily on alternate days, and gradually titrated up every 6 months to a maximum dose of 80 mg tds after 2–3 years. Metered dose 2% testosterone gel (Tostran) 10mg/metered application (0.5gms gel). Commence at 10 mg (1 metered application = 0.5gms gel) and increase to 2 metered dose applications daily if necessary for pubertal induction. Increase gradually (every 6 months) to adult dose of 60 – 80 mg of testosterone daily (3-4gms gel) if full replacement required. Doses extrapolated form adult dose. Apply thin layer of gel on clean, dry, healthy skin such as shoulders, arms or abdomen. Allow to dry before dressing. Be careful to avoid potential cross-contamination – wash hands with soap and water after applying gel. Preferably apply at bedtime, and avoid shower or bath for at least 6 hours. Should not be applied on genital area as can cause local irritation.
Dose and Administration. Preparation: Enteric Coated tablets improve gastrointestinal tolerability. Starting dose and titration 500 mg daily for first week, 500 mg bd for second week, 1g mane 500 mg nocte for third week, maintenance dose 1g bd. If inadequate response on 2g, Increase to 3g per day in divided doses.

Related to Dose and Administration

  • General and Administrative Costs means reasonable, normal and customary expenses and costs paid or payable that are classified as general and administrative costs, including salaries and all other compensation to the management of the Borrower, consulting fees, salary, rent, supplies, travel and entertainment, insurance, accounting, legal, engineering and broker related fees, required to manage the affairs of the Borrower.

  • Notice and Administration Costs means the costs, fees, and expenses that are incurred by the Claims Administrator and/or Lead Counsel in connection with: (i) providing notices to the Settlement Class; and (ii) administering the Settlement, including but not limited to the Claims process, as well as the costs, fees, and expenses incurred in connection with the Escrow Account.

  • Notice and Administration Expenses means all costs, fees, and expenses incurred in connection with providing notice to the Settlement Class and the administration of the Settlement, including but not limited to: (i) providing notice of the proposed Settlement by mail, publication, and other means to Settlement Class Members; (ii) receiving and reviewing claims; (iii) applying the Plan of Allocation; (iv) communicating with Persons regarding the proposed Settlement and claims administration process; (v) distributing the proceeds of the Settlement; and (vi) fees related to the Escrow Account and investment of the Settlement Fund.

  • Fund Administrator means the fund administrator, manager, trustee or similar person with the primary administrative responsibilities for a Fund according to the relevant Fund Documents.

  • Self-administration means carrying and taking medication without the intervention of the school nurse, approved through the school district policy and restricted to students with asthma, other potentially life-threatening illnesses or life-threatening allergic reaction.

  • CFD Administrator means an official of the City, or designee thereof, responsible for determining the Special Tax Requirement and providing for the levy and collection of the Special Taxes.

  • Undisclosed Administration means, in relation to a Lender or its direct or indirect parent company, the appointment of an administrator, provisional liquidator, conservator, receiver, trustee, custodian or other similar official by a supervisory authority or regulator under or based on the law in the country where such Lender or its direct or indirect parent company is subject to home jurisdiction supervision if applicable law requires that such appointment is not to be publicly disclosed and such appointment has not been publicly disclosed.

  • Self-Administration of Medication means the individual manages and takes his or her own medication, identifies his or her medication and the times and methods of administration, places the medication internally in or externally on his or her own body without staff assistance upon written order of a physician, and safely maintains the medication without supervision.

  • Temporary Assistance for Needy Families-Unemployed Parent or "TANF-UP" means the Temporary Assistance for Needy Families program for families in which both natural or adoptive parents of a child reside in the home and neither parent is exempt from the Virginia Initiative for Employment Not Welfare (VIEW) participation under § 63.2-609.

  • Misadministration means the administration of:

  • Direct medical education costs means costs directly associated with the medical education of interns and residents or other medical education programs, such as a nursing education program or allied health programs, conducted in an outpatient setting, that qualify for payment as medical education costs under the Medicare program. The amount of direct medical education costs is determined from the hospital base-year cost reports and is inflated in determining the direct medical education rate.

  • Occupational therapy assistant means an individual who has met the requirements of the Board for

  • Health and Human Services or “HHS” includes HHSC and DSHS.

  • General education means the compulsory school attendance phase as referred to in section 3 of the South African Schools Act, 1996 (Act No. 84 of 1996); and

  • Parent counseling and training means assisting parents in understanding the special needs of their child and providing parents with information about child development, and helping parents to acquire the necessary skills that will allow them to support the implementation of their child's IEP.

  • Free appropriate public education means special education and related services that:

  • Medication administration means the direct application of medications by injection, inhalation, ingestion, or any other means to an individual receiving services by (i) persons legally permitted to administer medications or (ii) the individual at the direction and in the presence of persons legally permitted to administer medications.

  • Medical Officer of Health means the Medical Officer of Health for the Regional Municipality of York;

  • CFO means an individual who acted as chief financial officer of the Company, or acted in a similar capacity, for any part of the most recently completed financial year;

  • Data Protection Officer takes the meaning given in the UK GDPR;

  • Public safety officer means a member serving a public

  • Legal Services means services of a legal or financial nature and includes any part of such services, and for the avoidance of doubt, includes (without limitation):-

  • Medical Review Officer (MRO means a licensed M.D. or D.O. with knowledge of drug abuse disorders, employed or used by the City to review drug results in accordance with this procedure.

  • Chief Administrative Officer (CAO means the person appointed to the position of chief administrative officer for the Town of Okotoks within the meaning of the Municipal Government Act;

  • Drug enforcement administration means the drug enforcement

  • Physical therapist assistant means an individual who is licensed/certified by a state and who assists the physical therapist in selected components of physical therapy.